Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Anus Neoplasms 2Rectal Neoplasms 1HIV Infections 1Anal Canal Carcinoma 1

Interventions

Specimen Handling 218pembrolizumab 200Magnetic Resonance Spectroscopy 196Carboplatin 173Cisplatin 137Biopsy 133Nivolumab 131Paclitaxel 116Cyclophosphamide 113Radiotherapy 110Gemcitabine 103Dexamethasone 91durvalumab 90atezolizumab 76Radiation 71Lenalidomide 71Rituximab 68Pemetrexed 67Doxorubicin 67Bevacizumab 65Docetaxel 62Ipilimumab 59Etoposide 56olaparib 55Fluorouracil 52venetoclax 51Radiosurgery 50Oxaliplatin 50Taxes 49Prednisone 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Proctoscopy × 90 days × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡